Compare AANJANEYA LIFECARE with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS SUN PHARMA DR. DATSONS LABS/
SUN PHARMA
 
P/E (TTM) x -10.9 28.5 - View Chart
P/BV x 0.2 2.5 6.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 DR. DATSONS LABS   SUN PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
SUN PHARMA
Mar-19
DR. DATSONS LABS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs126679 18.5%   
Low Rs31375 8.2%   
Sales per share (Unadj.) Rs133.0121.1 109.8%  
Earnings per share (Unadj.) Rs0.213.4 1.1%  
Cash flow per share (Unadj.) Rs6.620.7 31.9%  
Dividends per share (Unadj.) Rs02.75 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs128.8172.6 74.6%  
Shares outstanding (eoy) m31.662,399.26 1.3%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.64.4 13.5%   
Avg P/E ratio x516.139.4 1,309.8%  
P/CF ratio (eoy) x11.825.5 46.5%  
Price / Book Value ratio x0.63.1 19.9%  
Dividend payout %020.6 0.0%   
Avg Mkt Cap Rs m2,4771,264,650 0.2%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m5659,671 0.1%   
Avg. sales/employee Rs ThNM16,608.1-  
Avg. wages/employee Rs ThNM3,409.6-  
Avg. net profit/employee Rs ThNM1,833.8-  
INCOME DATA
Net Sales Rs m4,211290,659 1.4%  
Other income Rs m7910,255 0.8%   
Total revenues Rs m4,289300,914 1.4%   
Gross profit Rs m56963,076 0.9%  
Depreciation Rs m20417,533 1.2%   
Interest Rs m4305,553 7.7%   
Profit before tax Rs m1350,246 0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m66,009 0.1%   
Profit after tax Rs m532,093 0.0%  
Gross profit margin %13.521.7 62.2%  
Effective tax rate %48.012.0 401.6%   
Net profit margin %0.111.0 1.0%  
BALANCE SHEET DATA
Current assets Rs m6,852310,692 2.2%   
Current liabilities Rs m6,711173,396 3.9%   
Net working cap to sales %3.347.2 7.1%  
Current ratio x1.01.8 57.0%  
Inventory Days Days16199 162.4%  
Debtors Days Days318112 285.5%  
Net fixed assets Rs m3,673232,477 1.6%   
Share capital Rs m3172,399 13.2%   
"Free" reserves Rs m3,761411,691 0.9%   
Net worth Rs m4,078414,091 1.0%   
Long term debt Rs m1,67115,226 11.0%   
Total assets Rs m12,633646,938 2.0%  
Interest coverage x1.010.0 10.2%   
Debt to equity ratio x0.40 1,114.4%  
Sales to assets ratio x0.30.4 74.2%   
Return on assets %3.45.8 59.2%  
Return on equity %0.17.8 1.5%  
Return on capital %7.710.2 75.5%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96466,025 1.5%   
Fx outflow Rs m60738,610 1.6%   
Net fx Rs m35727,415 1.3%   
CASH FLOW
From Operations Rs m1,34521,965 6.1%  
From Investments Rs m-2,256-6,813 33.1%  
From Financial Activity Rs m-1,200-27,305 4.4%  
Net Cashflow Rs m-2,111-8,442 25.0%  

Share Holding

Indian Promoters % 4.5 63.7 7.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 5.1 -  
FIIs % 1.4 23.0 5.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 8.3 1,133.7%  
Shareholders   20,807 133,026 15.6%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON   PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - ALEMBIC LTD COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS